A comparative, randomised, two period, multi-center, cross-over 14 weeksbioequivalence study of Tobramycin PARI (T100) versus TOBI® (Novartis) incystic fibrosis patients with bronchopulmonary chronic Pseudomonasaeruginosa infection - T-100 BE A comparative, randomised, two period, multi-center, cross-over 14 weeksbioequivalence study of Tobr ...
A comparative, randomised, two period, multi-center, cross-over 14 weeksbioequivalence study of Tobramycin PARI (T100) versus TOBI® (Novartis) incystic fibrosis patients with bronchopulmonary chronic Pseudomonasaeruginosa infection - T-100 BE A comparative, randomised, two period, multi-center, cross-over 14 weeksbioequivalence study of Tobr ...
Product Name: Tobramycin Product Code: T100 INN or Proposed INN: Tobramycin Other descriptive name: Tobramycinum Trade Name: TOBI® INN or Proposed INN: TOBRAMYCIN Product Name: Tobramycin Product Code: T100 INN or Proposed INN: Tobramycin Other descriptive name: Tob ...
Randomized, open labeled, multi center, active controlled, parallel 28 days safety and bioavailability study of Tobramycin 100 PARI nebulized with eFlow® versus TOBI® nebulized with PARI LC PLUS® in cystic fibrosis patients with Pseudomonas Aeruginosa infections Randomized, open labeled, multi center, active controlled, parallel 28 days safety and bioavailabili ...
Randomized, open labeled, multi center, active controlled, parallel 28 days safety and bioavailability study of Tobramycin 100 PARI nebulized with eFlow® versus TOBI® nebulized with PARI LC PLUS® in cystic fibrosis patients with Pseudomonas Aeruginosa infections Randomized, open labeled, multi center, active controlled, parallel 28 days safety and bioavailabili ...
Product Name: Tobramycin 100 PARI Product Code: T 100 PARI Other descriptive name: tobramycinum Trade Name: TOBI Other descriptive name: tobramycinumProduct Name: Tobramycin 100 PARI Product Code: T 100 PARI Other descriptive name: tobramycinum Trade N ...